Cellebrite DI is experiencing one of its sharpest weekly declines in recent memory, down 30% to $11.14, even as options positioning swings aggressively to the buy side — a split signal that makes this week's setup genuinely unusual.
The clearest divergence sits in the options market. Traders have turned sharply bullish, with the put/call ratio collapsing to 0.19 on August 14 — more than four standard deviations below its 20-day average of 0.33. That's close to the 52-week low of 0.13, and it represents a sudden reversal from weeks of steady, flat PCR readings in the 0.32–0.34 range. The scale of the call-side skew suggests some investors are betting that the post-earnings selloff is overdone and reaching for upside exposure at depressed levels.
That stock fell because earnings delivered a genuine shock. A single session on August 13 erased nearly 27% of the share price — the only print in the recent history — dragging the one-month decline to 31%. The sell-off was steep enough that the stock closed Thursday at $11.14, despite a 3% partial bounce on Friday. Peers closed the week broadly flat to modestly lower: NOW fell under 1%, gained around 2%, and added nearly 11%. The magnitude of CLBT's move was entirely idiosyncratic.
Short positioning is not telling an aggressive story. Short interest rose about 10% over the week to 3.3% of the free float — a drift rather than a surge — and with availability running at 737%, the lending pool remains loose. More than seven shares are available to borrow for every one currently shorted. Cost to borrow has crept up 33% over the past month but still sits at just 0.55%, firmly in the low-cost range. The short score of 45.7 is mid-range, barely moved from where it was two weeks ago. There is no meaningful squeeze setup here, and no sign of a crowded short rebuilding rapidly after the earnings drop.
The analyst community took a coordinated knife to price targets on August 14, the day after the results. JP Morgan's Brian Essex trimmed his target from $20 to $16 while keeping his Overweight rating. DA Davidson cut from $22 to $15. Lake Street dropped from $21 to $15. Needham went further, lowering to $12.50 from $15. Every firm that moved did so in the same direction, and every firm maintained a positive rating. The consensus mean target now rests around $15.36, implying roughly 38% upside from current levels — but that figure is still settling as firms update post-earnings. Bulls lean on Cellebrite's government and law enforcement franchise and consistent revenue growth; bears point to the same concentration as a risk, highlighting budget-cycle exposure and the longer-term threat from smartphone manufacturers hardening their security stacks. Valuation multiples compressed sharply alongside the price: P/E fell to 17.8x (down more than 8x over 30 days) and EV/EBITDA dropped to 12.5x, a reset that re-rates the stock from growth to something approaching fair value on trailing numbers, though the EPS surprise factor score of 27 and forward EPS growth estimate turning negative keep the quality and growth pillars weak.
Institutional ownership shows some notable active-manager accumulation heading into the print. BlackRock added 2.3 million shares in the period ending July 31. Phoenix Investments added 2 million. Capital Research added 1.7 million shares through June. Artisan Partners added over 1 million. That institutional buying happened at prices meaningfully above where the stock trades today, and none of those positions have had time to be reported post-earnings. Separately, CEO Thomas Hogan sold 139,713 shares on August 12 at roughly $15.39 — before the worst of the drop — collecting $2.15 million. That sale followed an equity award of 339,484 shares the prior day, which is the mechanical context for the transaction, though the timing relative to earnings results is worth noting.
The next scheduled earnings event is not yet confirmed. What to watch is whether the institutional buyers who added through Q2 treat the $11–12 area as an opportunity to add further, or whether the earnings miss triggers a reassessment of the thesis that brings those recently-added positions back to market.
See the live data behind this article on ORTEX.
Open CLBT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
